Stock Research for ABSCF


Featured Broker: Ally Invest

Get the due diligence for another stock.


ABSCF Stock Chart & Research Data

The ABSCF chart settings shown below allow you to select time intervals of 1 min, 30 mins, an hour or by day - week - month. There is also the ability to change the ABSCF chart style to candles, hollow candles, bars, lines or add various indicators. You can even add a symbol and compare history.


ABSCF Due diligence Resources & Stock Charts

The ABSCF stock resources shown below were gathered to cut back on time by allowing you to visit multiple sites at once. For your convenience each link clicked will open in a window. In addition to the individual links there is a button at the bottom that will allow you to open all the links at the same time. Note opening all links at once may not work with all browsers. Some browsers block multiple windows, to resolve this please allow that site to use pop-ups.

The Four Most Popular Resources

CNN View ABSCF Detailed Price Forecast - CNN Money CNN View ABSCF Detailed Summary - Google Finance
Yahoo View ABSCF Detailed Summary - Yahoo! Finance Zacks View ABSCF Stock Research & Analysis -

Stock Analysis

TradeIdeas View ABSCF Trends & Analysis - Trade-Ideas Barrons View ABSCF Major Holders - Barrons
NASDAQ View ABSCF Call Transcripts - NASDAQ Seeking View ABSCF Breaking News & Analysis - Seeking Alpha
Spotlight View ABSCF Annual Report - OTC Report View ABSCF OTC Short Report -
TradeKing View ABSCF Fundamentals - TradeKing Charts View ABSCF SEC Filings - Bar Chart
WSJ View Historical Prices for ABSCF - The WSJ Morningstar View Performance/Total Return for ABSCF - Morningstar
MarketWatch View the Analyst Estimates for ABSCF - MarketWatch CNBC View the Earnings History for ABSCF - CNBC
StockMarketWatch View the ABSCF Earnings - StockMarketWatch MacroAxis View ABSCF Buy or Sell Recommendations - MacroAxis
Bullish View the ABSCF Bullish Patterns - American Bulls Short Pains View ABSCF Short Pain Metrics -

Social Media Mentions

StockTwits View ABSCF Stock Mentions - StockTwits PennyStocks View ABSCF Stock Mentions - PennyStockTweets
Twitter View ABSCF Stock Mentions - Twitter Invest Hub View ABSCF Investment Forum News - Investor Hub
Yahoo View ABSCF Stock Mentions - Yahoo! Message Board Seeking Alpha View ABSCF Stock Mentions - Seeking Alpha

Financial & Transaction Holdings

SECform4 View Insider Transactions for ABSCF - Insider Cow View Insider Transactions for ABSCF - Insider Cow
CNBC View ABSCF Major Holdings Summary - CNBC OTC Markets View Insider Disclosure for ABSCF - OTC Markets
Yahoo View Insider Transactions for ABSCF - Yahoo! Finance NASDAQ View Institutional Holdings for ABSCF - NASDAQ

Stock Charts

FinViz View ABSCF Stock Insight & Charts - StockCharts View ABSCF Investment Charts -
BarChart View ABSCF Stock Overview & Charts - BarChart Trading View View ABSCF User Generated Charts - Trading View

Latest Financial News for ABSCF

AB Science provides an update on the restructuring of its clinical development department in 2018
Posted on Wednesday December 19, 2018

FR0010557264 - AB), a pharmaceutical company specialized in the research and development of protein kinase inhibitors (PKIs), has completed reorganization of its clinical development activity to ensure compliance with good clinical practices as a consequence of the ANSM decision to put AB Science studies on clinical hold in France. AB Science provides here the main achievements of this restructuring.

AB Science announces that the masitinib phase 3 study in Alzheimer's disease has completed patient recruitment
Posted on Monday October 22, 2018

FR0010557264 - AB), a pharmaceutical company specialized in the research, development and marketing of protein kinase inhibitors (PKIs), announces today that the masitinib phase 3 study in Alzheimer`s disease has completed patient recruitment.

What Are The Drivers Of AB Science SA’s (EPA:AB) Risks?
Posted on Friday September 14, 2018

Anyone researching AB Science SA (EPA:AB) might want to consider the historical volatility of the share price. Volatility is considered to be a measure of risk in modern finance theory.Read More...

AB Science reports positive IDMC recommendation to continue the study based on a trend analysis of the masitinib phase 2/3 study in refractory metastatic colorectal cancer
Posted on Monday July 23, 2018

FR0010557264 - AB), a pharmaceutical company specialized in research, development and marketing of protein kinase inhibitors (PKIs), announces the positive recommendation of the Independent Data Monitoring Committee (IDMC) to continue, based on the planned trend-analysis, the study AB12010 in the third and fourth-line treatment of metastatic colorectal cancer. Study AB12010 is an open-label, randomized, adaptive phase 2/3 study comparing the efficacy and safety of masitinib in combination with FOLFIRI (irinotecan, 5-fluorouracil and folinic acid), versus Best Supportive Care in third or fourth line of treatment of patients with metastatic colorectal cancer.

Stock Market & Investing Books

Enter a stock symbol to view the stock details.